This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
It is a treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. per cent and 2.1
The combo therapy topped $10 billion in revenue last year for the first time since its approval in 2019. In general, the megablockbuster trend is skewing toward drugs that reach a wider range of patients, such as checkpoint inhibitors like Keytruda and GLP-1 weight loss and diabetes medications. billion last year.
Beyond these official sources, various healthcare societies and associations also contribute by publishing practical guides relevant to their specific disciplines.
The pharmacist in Malaysia, inspiring global peers with their fresh approach to diabetes care. It was a bold, but modest, step – funded by a small grant, but driven by a big ambition: to expand equitable access to meaningful, high-quality professional development for pharmacists, particularly in historically under-resourced settings.
November 21, 2019. Effect of acalabrutinib in combination with bendamustine plus rituximab on survival endpoints in older patients with mantle cell lymphoma: insights from the ECHO trial. healthbook TIMES Onco Hema. 2024;22(4):22-29. doi:10.36000/HBT.OH.2024.22.163 ClinicalTrials.gov. Updated February 19, 2025. Accessed May 14, 2025.
million fewer doses were administered in retail and clinical settings than in the prepandemic 2019-2020 season. Additionally, vaccination rates among Medicare beneficiaries 65 years and older reached only 48.3%, and nearly 9.2
Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants Lancet 2021 Sep 11;398(10304):957-980. Current Cardiology Reports 2019; 21. High Blood Pressure Facts. Accessed June 26, 2025. Epub 2021 Aug 24.
million deaths in 2019 alone. This post hoc secondary analysis, published by investigators in JAMA Network , aims to determine if this intervention had a spillover effect on antibiotic prescribing across the entire patient population. 1 Image credit: I Viewfinder | stock.adobe.com According to WHO, AMR accounted for 1.27
For example: Diabetes According to the Centers for Medicare and Medicaid Services , among Asian Americans, the diagnosed diabetes rate is 9.2%; this varies significantly by subgroupas high as 12.2% cases per 100,000 for non-Hispanic Whites, as of 2019). for Asian Indians and 10.4% for Filipinos, and as low as 5.6%
In 2019, the FDA approved avatrombopag’s expanded indication for treatment of adults with chronic immune thrombocytopenia (ITP) that hasn't responded satisfactorily to a previous therapy. June 27, 2019. It was initially approved in 2018 for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.
1,2 Tafamidis in the Treatment of ATTR-CM Initially approved in 2019 3 , tafamidis (Vyndamax; Pfizer) is a selective transthyretin (TTR) kinetic stabilizer that binds to thyroxine-binding sites on TTR tetramers, which prevents dissociation into monomers, or the breakdown into amyloid deposits that damage the heart in ATTR-CM. May 6, 2019.
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. link] Adeloye D, Song P, Zhu Y, Campbell H, Sheikh A, Rudan I; NIHR RESPIRE Global Respiratory Health Unit. Lancet Respir Med.2022;10(5):447-458. 2022;10(5):447-458.
September 9, 2019. trillion economic impact in 2020. May 21, 2025. Accessed May 27, 2025. Acura Pharmaceuticals engages Catalent Pharma Solutions to advance development of LTX-03. News release. FirstWord Pharma. Accessed May 27, 2025. Acura Pharmaceuticals, Inc. US Securities and Exchange Commission; 2025. Accessed May 27, 2025.
1,2 To better understand this relationship, researchers assessed 4754 patients with CLL/SLL who were treated with either venetoclax and obinutuzumab from April 2016 to August 2022 (n = 2104) or zanubrutinib from November 2019 to August 2023 (n = 2650).
1 The disease can range from mild to severe and is defined by major and minor criteria, most recently updated by the 2019 Guidelines for Diagnosis and Treatment of Adults with Community-Acquired Pneumonia by the American Thoracic Society (ATS) and Infectious Diseases Society of America (IDSA) ( Table 1 ).
3 In 2019, the FDA issued a warning about serious breathing problems when gabapentinoids are used concurrently with opioids or in patients with respiratory risk factors. Published December 2019. Subscribe Now!
December 12, 2019. How your oncology peers manage the complexities of care. Oncology Live ®. December 13, 2018. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development. Updated January 19, 2024. Accessed May 15, 2025. LinkedIn Workplace Learning Report 2024. LinkedIn Learning. Accessed May 15, 2025.
doi:10.2217/cer-2019-0059 Ganz ML, Chavan A, Dhanda R, Serbin M, Yonan C. J Clin Mov Disord. doi:10.1186/s40734-017-0051-5 Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8(13):1077-1088. J Med Econ. 2021;24(1):103-113.
It consolidates and replaces four previous guideline publications: Garis Panduan Kaunseling Ubat-ubatan, 2019 Garis Panduan Pelaksanaan Kaunseling Ubat-ubatan Secara Maya/Virtual, 2021 Topical Preparations Counselling Guide for Pharmacists, 2018 Garis Panduan Kaunseling Methadone. At the end of the day, patients are on their own.
For this reason, experts of a 2019 phase 3 trial assessed the clinical equivalence of IBI303 to Humira in patients with ankylosing spondylitis. Despite Humira’s approval in China, patients are often unable to receive treatment because of the high cost (approximately $2250 USD) per month.
million deaths in 2019, and this is predicted to increase to approximately 23 million annual deaths by 2030. Omega-3 fatty acids effects on inflammatory biomarkers and lipid profiles among diabetic and cardiovascular disease patients: a systematic review and meta-analysis. 1 CVDs are disorders affecting the heart and blood vessels.
2019:10(2). To properly and responsibly allocate these medications to patients, pharmacists and health professionals must develop proper literacy and adeptness at using new products such as Detect-A-Dose while maintaining adequate communication and multidisciplinary teamwork. REFERENCES 1. Delgado NL, Usuyama N, Hall AK, et al. 2020;8(4):216.
From 2019 to 2023, the percentage of centers using biosimilars increased from about 38.2% (n = 26) to 88.1% (n = 59). There was a slow uptake of infliximab biosimilar use among the ICN centers. Initially, only 1 center (1.9%) within ICN used an infliximab biosimilar in 2016, and five (8.2%) used an infliximab biosimilar in 2018.
031), and diagnosis between 2016 and 2018 (OR 1.93, P < 001) as well as 2019 and 2020 (1.88, P < 001). Following 2019 to 2020, use of these agents saw a slight decline and stabilization around 75%. 3 The utilization of HER2 therapies increased from 64.6% in 2013 to 80.9%
5 (May 2019): e13876, [link] [6] Jennifer Dickman Portz et al., LaManna, and Chanhyun Park, “Digital Divide Among Medicare Beneficiaries and the Diabetes Prevention Program,” American Journal of Preventive Medicine 67, no. [link] [5] Jan Walker et al., Developer Documentation,” CMS.gov , accessed June 4, 2025, [link] [8] Sahalu B.
Published 2019 May 2. Resistance Trends of Klebsiella pneumoniae Causing Urinary Tract Infections in Chongqing, 2011-2019. Antibiotic-mediated gut microbiome perturbation accelerates development of type 1 diabetes in mice. Ther Adv Urol. 2019;11:1756287219832172. doi:10.1177/1756287219832172 [2] Orenstein R, Wong ES.
Medicare spending on skin substitutes increased from $256 million in 2019 to more than $10 billion in 2024, the release said, according to Medicare Part B claims data. The model encourages tech-enabled patient engagement and will run through December 2031. “This includes input on nutrition counseling and physical activity.”
We organize all of the trending information in your field so you don't have to. Join 11,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content